---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-112734"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:37:40.278154+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology CMO Sophia Randolph resigns; separation includes $503,880 and accelerated vesting

## Summary
- CMO Sophia Randolph resigns effective Oct 11, 2024; she leaves to pursue other professional opportunities.
- Separation agreement includes $503,880 lump sum payment plus COBRA coverage for up to 18 months.
- Outstanding stock options and RSUs that would vest in 12 months post-separation will fully vest; options exercisable until July 11, 2026.
- Company will commence a search for a new Chief Medical Officer.
- She will provide transition consulting services via a consulting agreement for up to 18 months.

## SEC filing metadata
- accession: 0000950170-24-112734
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024112734/0000950170-24-112734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024112734/alxo-20240930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-112734
- JSON: https://secwatch.observer/filing/0000950170-24-112734.json
- Plain text: https://secwatch.observer/filing/0000950170-24-112734.txt

## Key facts
- Executive change
  Sophia Randolph resigned as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On September 30, 2024, Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology Holdings Inc. (the “Company”) informed the Company of her resignation from her position effective October 11, 2024, to pursue other professional opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024112734/0000950170-24-112734-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.